- Zacks Small Cap Research•2 months agoVKTX: Phase 2 Study of VK5211 for Hip Fracture Ongoing; Phase 2 Study of VK2809 for Hypercholersterolemia to Commence in mid-2016
Viking’s (VKTX) lead drug candidate is VK5211, a third-generation non-steroidal Selective Androgen Receptor Modulator (SARM) that is being developed for maintenance or improvement of lean body mass (LBM), bone mineral density (BMD), and function in patients recovering from non-elective hip fracture surgery. Hip fracture is associated with a number of morbidities, the majority of which are the result of deleterious changes in body composition following the injury.
Synta Pharmaceuticals Corp.NasdaqCM
After hours: 0.34-0.00 (-0.87%) as of 6:05 PM EDT
|52wk Range||0.15 - 2.23|
|Day's Range||0.27 - 0.40|
|Avg Vol (3m)||747,661|
As of 4:00 PM EDT. Market closed.